葛兰素史克的Arexvy RSV疫苗在中国接受老年人监管审查

2026-02-10 21:02

GlaxoSmithKline (GSK) said on Tuesday that China’s Center for Drug Evaluation has accepted its regulatory application for Arexvy (RSV [recombinant, adjuvanted] vaccine) for review. The vaccine is intended to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 and older.
If approved, Arexvy will be the first vaccine available to this population in China to help protect against the potentially serious consequences of RSV disease.
Respiratory Syncytial Virus vaccine (recombinant, adjuvanted) contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s (GSK) proprietary AS01E adjuvant before administration.

More on GSK